CY1111057T1 - ΥΠΟΚΑΤΕΣΤΗΜΕΝΑ ΠΑΡΑΓΩΓΑ ΤΗΣ 8-ΠΥΡΙΔΙΝΥΛΟ-ΔΙΥΔΡΟΣΠΕΙΡΟ-ΚΥΚΛΟΑΛΚΥΛΟ-ΠΥΡΙΜΙΔΟ 1,2-a ΠΥΡΙΜΙΔΙΝ-6-ΟΝΗΣ ΚΑΙ ΤΗΣ 8-ΠΥΡΙΜΙΔΙΝΥΛΟ-ΔΙΥΔΡΟΣΠΕΙΡΟ-ΚΥΚΛΟΑΛΚΥΛΟ-ΠΥΡΙΜΙΔΟ 1,2-a ΠΥΡΙΜΙΔΙΝ-6- ΟΝΗΣ ΚΑΙ Η ΧΡΗΣΗ ΑΥΤΩΝ ΕΝΑΝΤΙ ΤΩΝ ΝΕΥΡΟΕΚΦΥΛΙΣΤΙΚΩΝ ΝΟΣΩΝ - Google Patents
ΥΠΟΚΑΤΕΣΤΗΜΕΝΑ ΠΑΡΑΓΩΓΑ ΤΗΣ 8-ΠΥΡΙΔΙΝΥΛΟ-ΔΙΥΔΡΟΣΠΕΙΡΟ-ΚΥΚΛΟΑΛΚΥΛΟ-ΠΥΡΙΜΙΔΟ 1,2-a ΠΥΡΙΜΙΔΙΝ-6-ΟΝΗΣ ΚΑΙ ΤΗΣ 8-ΠΥΡΙΜΙΔΙΝΥΛΟ-ΔΙΥΔΡΟΣΠΕΙΡΟ-ΚΥΚΛΟΑΛΚΥΛΟ-ΠΥΡΙΜΙΔΟ 1,2-a ΠΥΡΙΜΙΔΙΝ-6- ΟΝΗΣ ΚΑΙ Η ΧΡΗΣΗ ΑΥΤΩΝ ΕΝΑΝΤΙ ΤΩΝ ΝΕΥΡΟΕΚΦΥΛΙΣΤΙΚΩΝ ΝΟΣΩΝInfo
- Publication number
- CY1111057T1 CY1111057T1 CY20101100761T CY101100761T CY1111057T1 CY 1111057 T1 CY1111057 T1 CY 1111057T1 CY 20101100761 T CY20101100761 T CY 20101100761T CY 101100761 T CY101100761 T CY 101100761T CY 1111057 T1 CY1111057 T1 CY 1111057T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cycloalkyl
- dihydrospiro
- pyrimido
- pyrimidin
- ring
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Η εφεύρεση σχετίζεται με ένα παράγωγο διυδροσπειρο-[κυκλοαλκυλο]- πυριμιδόνης που αναπαριστάται από τον τύπο (I) ή ένα άλας αυτού: όπου το Χ αναπαριστά δύο άτομα υδρογόνου, ένα άτομο θείου, ένα άτομο οξυγόνου ή μία αλκυλομάδα C1-2 και ένα άτομο υδρογόνου· το Υ αναπαριστά έναν δεσμό, μία καρβονυλομάδα, μία μεθυλενομάδα η οποία υποκαθίσταται προαιρετικά· το R1 αναπαριστά έναν δακτύλιο 2, 3 ή 4-πυριδίνης ή έναν δακτύλιο 2, 4 ή 5-πυριμιδίνης, όπου ο δακτύλιος είναι προαιρετικά υποκατεστημένος· το R2 αναπαριστά έναν δακτύλιο βενζολίου ή έναν δακτύλιο ναφθαλενίου· όπου οι δακτύλιοι προαιρετικά υποκατεστημένοι∙ το R3 αναπαριστά ένα άτομο υδρογόνου, μία αλκυλομάδα C1-6, ή ένα άτομο αλογόνου∙ το m αναπαριστά 1 έως 4, το n αναπαριστά 0 έως 3, το p αναπαριστά 0 έως 2, το q αναπαριστά 0 έως 2, όπου το p+q είναι κατώτερο του 4. Η εφεύρεση σχετίζεται επίσης με ένα φάρμακο το οποίο περιλαμβάνει το εν λόγω παράγωγο ή ένα άλας αυτού ως ενεργό συστατικό, το οποίο χρησιμοποιείται για προληπτική και/ ή θεραπευτική αγωγή μίας νευροεκφυλιοτικής νόσου που προκαλείται από ανώμαλη ενεργότητα της GSK3β, όπως η νόσος Alzheimer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03290569A EP1454909B1 (en) | 2003-03-07 | 2003-03-07 | 8'-pyridinyl-dihydrospiro (cycloalkyl) -pyrimido (1,2-a) pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro (cycloalkyl) pyrimido (1,2-a) pyrimidin-6 derivatives -one and their use against neurodegenerative diseases |
EP04717643A EP1603915B1 (en) | 2003-03-07 | 2004-03-05 | SUBSTITUTED 8 -PYRIDINYL-DIHYDROSPIRO- CYCLOALKYL -PYRIMIDO 1,2-a PYRIMIDIN-6-ONE AND 8 -PYRIMIDIN YL-DIHYDROSPIRO- CYCLOALKYL -PYRIMIDO 1,2-a PYRIMIDIN-6-ONE DERIVATIVES AND THEIR USE AGAINST NEUROGENERATIVE DISEASES |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1111057T1 true CY1111057T1 (el) | 2015-06-11 |
Family
ID=32799103
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20101100761T CY1111057T1 (el) | 2003-03-07 | 2010-08-17 | ΥΠΟΚΑΤΕΣΤΗΜΕΝΑ ΠΑΡΑΓΩΓΑ ΤΗΣ 8-ΠΥΡΙΔΙΝΥΛΟ-ΔΙΥΔΡΟΣΠΕΙΡΟ-ΚΥΚΛΟΑΛΚΥΛΟ-ΠΥΡΙΜΙΔΟ 1,2-a ΠΥΡΙΜΙΔΙΝ-6-ΟΝΗΣ ΚΑΙ ΤΗΣ 8-ΠΥΡΙΜΙΔΙΝΥΛΟ-ΔΙΥΔΡΟΣΠΕΙΡΟ-ΚΥΚΛΟΑΛΚΥΛΟ-ΠΥΡΙΜΙΔΟ 1,2-a ΠΥΡΙΜΙΔΙΝ-6- ΟΝΗΣ ΚΑΙ Η ΧΡΗΣΗ ΑΥΤΩΝ ΕΝΑΝΤΙ ΤΩΝ ΝΕΥΡΟΕΚΦΥΛΙΣΤΙΚΩΝ ΝΟΣΩΝ |
Country Status (26)
Country | Link |
---|---|
US (2) | US7294632B2 (el) |
EP (2) | EP1454909B1 (el) |
JP (1) | JP4639182B2 (el) |
KR (1) | KR101069984B1 (el) |
CN (1) | CN100463908C (el) |
AR (1) | AR043485A1 (el) |
AT (1) | ATE469153T1 (el) |
AU (1) | AU2004218250B2 (el) |
BR (1) | BRPI0408189A (el) |
CA (1) | CA2516937C (el) |
CY (1) | CY1111057T1 (el) |
DE (1) | DE602004027354D1 (el) |
DK (1) | DK1603915T3 (el) |
EA (1) | EA008172B1 (el) |
ES (1) | ES2346311T3 (el) |
HK (1) | HK1085740A1 (el) |
IL (1) | IL170461A (el) |
MX (1) | MXPA05009574A (el) |
NO (1) | NO20054140L (el) |
NZ (1) | NZ542135A (el) |
PL (1) | PL1603915T3 (el) |
PT (1) | PT1603915E (el) |
SI (1) | SI1603915T1 (el) |
TW (1) | TWI320785B (el) |
WO (1) | WO2004078760A1 (el) |
ZA (1) | ZA200507107B (el) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7759353B2 (en) * | 2005-06-14 | 2010-07-20 | Schering Corporation | Substituted spiro iminopyrimidinones as aspartyl protease inhibitors, compositions, and methods of treatment |
JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス,インコーポレイティド | ムスカリン性受容体調節による神経発生 |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
AU2006304787A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
EP2377531A2 (en) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
EP1992624A1 (en) | 2007-05-16 | 2008-11-19 | Sanofi-Aventis | Heteroarylamide pyrimidone compounds |
EP1992625A1 (en) * | 2007-05-16 | 2008-11-19 | Sanofi-Aventis | Arylamide pyrimidone compounds |
EP1992621A1 (en) * | 2007-05-16 | 2008-11-19 | Sanofi-Aventis | Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases |
EP1992620A1 (en) | 2007-05-16 | 2008-11-19 | Sanofi-Aventis | Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases |
EP2138488A1 (en) | 2008-06-26 | 2009-12-30 | sanofi-aventis | 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases |
EP2138493A1 (en) | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted pyrimidone derivatives |
EP2138494A1 (en) | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted alkyl pyrimidin-4-one derivatives |
EP2138495A1 (en) | 2008-06-26 | 2009-12-30 | sanofi-aventis | Substituted pyrimido[2,1-a]isoquinolin-4-one derivatives |
EP2138492A1 (en) | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted pyrimidin-4-one derivatives |
EP2138485A1 (en) | 2008-06-26 | 2009-12-30 | sanofi-aventis | Substituted N-Oxide pyrazine derivatives |
EP2138498A1 (en) * | 2008-06-26 | 2009-12-30 | sanofi-aventis | Substituted tricyclic derivatives against neurodegenerative diseases |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
RU2561130C2 (ru) | 2009-07-02 | 2015-08-20 | Санофи | НОВЫЕ ПРОИЗВОДНЫЕ 1,2,3,4-ТЕТРАГИДРОПИРИМИДО{1,2-a}ПИРИМИДИН-6-ОНА, ИХ ПОЛУЧЕНИЕ И ФАРМАЦЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ |
US8815853B2 (en) | 2010-12-23 | 2014-08-26 | Sanofi | Pyrimidinone derivatives, preparation thereof and pharmaceutical use thereof |
FR2992314B1 (fr) | 2012-06-22 | 2015-10-16 | Sanofi Sa | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique |
FR2992316A1 (fr) | 2012-06-22 | 2013-12-27 | Sanofi Sa | Derives de pyrimidinones, leur preparation et leur application en therapeutique |
CA2945263A1 (en) | 2014-04-09 | 2015-10-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2812636A1 (fr) * | 2000-08-02 | 2002-02-08 | Novapharme | Nouveaux derives 2-phenyl imidazo[1.2-a]pyrimidin-5-ones et 2-phenyl 2,3-dihydro imidazo[1,2-a]pyrimidin-5-ones |
EP1184383A1 (en) * | 2000-09-01 | 2002-03-06 | Sanofi-Synthelabo | 9-[Alkyl], 9-[(heteroaryl)alkyl] and 9-[(aryl)alkyl]-2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one derivatives |
EP1184385A1 (en) * | 2000-09-01 | 2002-03-06 | Sanofi-Synthelabo | 1-[Alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)-one derivatives |
SI1315731T1 (en) * | 2000-09-01 | 2005-02-28 | Sanofi-Aventis | 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1h)one derivatives |
EP1295884A1 (en) * | 2001-09-21 | 2003-03-26 | Sanofi-Synthelabo | 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 7-Pyrimidinyl-2,3-Dihydroimidazo[1,2-a]Pyrimidin-5(1H)one derivatives |
PT1674456E (pt) * | 2001-09-21 | 2008-09-11 | Sanofi Aventis | Utilização de 2-fluoro-3-cetoésteres para preparar 3-fluoro- 6,7,8,9-tetra-hidro-4-h-pirimido[1,2-a]pirimidin-4-onas |
EP1430056B1 (en) * | 2001-09-21 | 2005-10-26 | Sanofi-Aventis | Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives for neurodegenerative disorders |
EP1295885A1 (en) * | 2001-09-21 | 2003-03-26 | Sanofi-Synthelabo | Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1H)one derivatives |
-
2003
- 2003-03-07 EP EP03290569A patent/EP1454909B1/en not_active Withdrawn - After Issue
-
2004
- 2004-03-05 DK DK04717643.3T patent/DK1603915T3/da active
- 2004-03-05 AR ARP040100694A patent/AR043485A1/es not_active Application Discontinuation
- 2004-03-05 NZ NZ542135A patent/NZ542135A/en not_active IP Right Cessation
- 2004-03-05 EA EA200501241A patent/EA008172B1/ru not_active IP Right Cessation
- 2004-03-05 ZA ZA200507107A patent/ZA200507107B/en unknown
- 2004-03-05 ES ES04717643T patent/ES2346311T3/es not_active Expired - Lifetime
- 2004-03-05 BR BRPI0408189-7A patent/BRPI0408189A/pt not_active IP Right Cessation
- 2004-03-05 MX MXPA05009574A patent/MXPA05009574A/es active IP Right Grant
- 2004-03-05 PL PL04717643T patent/PL1603915T3/pl unknown
- 2004-03-05 EP EP04717643A patent/EP1603915B1/en not_active Expired - Lifetime
- 2004-03-05 WO PCT/EP2004/003051 patent/WO2004078760A1/en active Application Filing
- 2004-03-05 AT AT04717643T patent/ATE469153T1/de active
- 2004-03-05 SI SI200431465T patent/SI1603915T1/sl unknown
- 2004-03-05 JP JP2006504813A patent/JP4639182B2/ja not_active Expired - Fee Related
- 2004-03-05 AU AU2004218250A patent/AU2004218250B2/en not_active Ceased
- 2004-03-05 PT PT04717643T patent/PT1603915E/pt unknown
- 2004-03-05 CA CA2516937A patent/CA2516937C/en not_active Expired - Fee Related
- 2004-03-05 DE DE602004027354T patent/DE602004027354D1/de not_active Expired - Lifetime
- 2004-03-05 TW TW093105914A patent/TWI320785B/zh not_active IP Right Cessation
- 2004-03-05 CN CNB2004800109973A patent/CN100463908C/zh not_active Expired - Fee Related
-
2005
- 2005-08-23 IL IL170461A patent/IL170461A/en not_active IP Right Cessation
- 2005-09-06 KR KR1020057016622A patent/KR101069984B1/ko not_active IP Right Cessation
- 2005-09-06 NO NO20054140A patent/NO20054140L/no not_active Application Discontinuation
- 2005-09-07 US US11/220,999 patent/US7294632B2/en not_active Expired - Fee Related
-
2006
- 2006-07-14 HK HK06107902.6A patent/HK1085740A1/xx not_active IP Right Cessation
-
2007
- 2007-10-02 US US11/866,142 patent/US7507743B2/en not_active Expired - Fee Related
-
2010
- 2010-08-17 CY CY20101100761T patent/CY1111057T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1111057T1 (el) | ΥΠΟΚΑΤΕΣΤΗΜΕΝΑ ΠΑΡΑΓΩΓΑ ΤΗΣ 8-ΠΥΡΙΔΙΝΥΛΟ-ΔΙΥΔΡΟΣΠΕΙΡΟ-ΚΥΚΛΟΑΛΚΥΛΟ-ΠΥΡΙΜΙΔΟ 1,2-a ΠΥΡΙΜΙΔΙΝ-6-ΟΝΗΣ ΚΑΙ ΤΗΣ 8-ΠΥΡΙΜΙΔΙΝΥΛΟ-ΔΙΥΔΡΟΣΠΕΙΡΟ-ΚΥΚΛΟΑΛΚΥΛΟ-ΠΥΡΙΜΙΔΟ 1,2-a ΠΥΡΙΜΙΔΙΝ-6- ΟΝΗΣ ΚΑΙ Η ΧΡΗΣΗ ΑΥΤΩΝ ΕΝΑΝΤΙ ΤΩΝ ΝΕΥΡΟΕΚΦΥΛΙΣΤΙΚΩΝ ΝΟΣΩΝ | |
CY1109890T1 (el) | ΠΑΡΑΓΩΓΑ 8-ΥΠΟΚΑΤΕΣΤΗΜΕΝΗΣ-6,7,8,9- ΤΕΤΡΑΫΔΡΟΠΥΡΙΜΙΔΟ[1,2-α] ΠΥΡΙΜΙΔΙΝ-4-ΟΝΗΣ | |
CY1107982T1 (el) | Υποκατεστημενα παραγωγα 8’-πυρι(μι)δινυλο-διϋδροσπειρο-[κυκλοαλκυλαμινο]-πυριμιδο[1,2-a]πυριμιδιν-6ονης. | |
EA200801134A1 (ru) | Замещенные бициклические пиримидоновые производные | |
EA200501311A1 (ru) | ПРОИЗВОДНЫЕ ЗАМЕЩЁННОГО 8-ПЕРФТОРАЛКИЛ-6,7,8,9-ТЕТРАГИДРОПИРИМИДО[1,2-a]ПИРИМИДИН-4-ОНА | |
CY1117014T1 (el) | Παραγωγο συμπυκνωμενης αμινοδιυδροθιαζινης | |
CY1108347T1 (el) | Ενωσεις ιμιδαζολιου για την θεραπεια νευροεκφυλιστικων διαταραχων | |
EA200970455A1 (ru) | ЗАМЕЩЕННЫЙ 8-ПИПЕРИДИНИЛ-2-ПИРИДИНИЛПИРИМИДО[1,2-a]ПИРИМИДИН-6-ОН И ПРОИЗВОДНЫЕ 8-ПИПЕРИДИНИЛ-2-ПИРИМИДИНИЛПИРИМИДО[1,2-a]ПИРИМИДИН-6-ОНА | |
CY1118390T1 (el) | Θεραπευτικος παραγων για τη φλεγμονωδη νοσο του εντερου | |
EA201070896A1 (ru) | ЗАМЕЩЕННЫЕ АРИЛАМИДДИАЗЕПИНОПИРИМИДОНОВЫЕ ПРОИЗВОДНЫЕ ДЛЯ ЛЕЧЕНИЯ НЕЙРОДЕГЕНЕРАТИВНЫХ ЗАБОЛЕВАНИЙ, ВЫЗВАННЫХ АНОМАЛЬНОЙ АКТИВНОСТЬЮ GSK3β | |
CY1112601T1 (el) | Υποκατεστημενα παραγωγα 1-πιπεριδιν-4-υλ-4-πυρρολιδιν-3-υλ-πιπεραζινης και χρηση αυτων ως ανταγωνιστων νευροκινινης | |
NO20071719L (no) | Pyridylinhibitorer for "hedgehog"-signalisering | |
BRPI0818626A2 (pt) | n-fenil-bipirrolidina carboxamidas substituída e uso terapêutico da mesma | |
BRPI0818581A2 (pt) | Carboxamidas n-fenil-bipirrolidina substituídas e uso terapêutico das mesmas | |
CY1113505T1 (el) | Νεο παραγωγο ανθρανιλικου οξεος ή αλας αυτου | |
CY1105631T1 (el) | Υποκατεστημενα παραγωγα καρβοστυριλης ως αγωνιστες 5-ητ1α υποτυπου δεκτη | |
EA200970598A1 (ru) | Замещенные производные гетероарилпиридопиримидона | |
EA200400936A1 (ru) | ГЕТЕРОАРИЛЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 2-ПИРИДИНИЛ- И 2-ПИРИМИДИНИЛ-6,7,8,9-ТЕТРАГИДРОПИРИМИДО[1,2-a]ПИРИМИДИН-4-ОНА | |
HUP0402019A2 (hu) | CCR5 antagonistaként alkalmazható piperidinszármazékok és ezeket tartalmazó gyógyszerkészítmények | |
EA201170094A1 (ru) | Производные замещенного пиримидо[2,1-а]изохинолин-4-она | |
EA200970637A1 (ru) | 2-замещенные-6-гетероциклилпроизводные пиримидона в качестве ингибиторов тау-протеинкиназы | |
CY1124346T1 (el) | ΠΑΡΑΓΩΓΑ ΧΡΩΜΑΝΙΟΥ, ΙΣΟΧΡΩΜΑΝΙΟΥ ΚΑΙ ΔΙΥΔΡΟΪΣΟΒΕΝΖΟΦΟΥΡΑΝΙΟΥ ΩΣ mGluR2-APNHTIKOI ΑΛΛΟΣΤΕΡΙΚΟΙ ΔΙΑΜΟΡΦΩΤΕΣ, ΣΥΝΘΕΣΕΙΣ, ΚΑΙ ΧΡΗΣΗ ΑΥΤΩΝ | |
CY1111132T1 (el) | Παραγωγα υποκατεστημενης 2-(διαζα-δικυκλο-αλκυλ)-πυριμιδονης | |
TH82134A (th) | อนุพันธ์ซับสทิทิวเทด 2-(ไอแอซา-ไบไซโคล-แอลคิล)-ไพริมิโดน |